Market OverviewFinlify
Price Date: 2026/09/11
SYK logo

SYK - Stryker Corporation

A medical technology company specializing in orthopedic implants, surgical equipment, and neurotechnology — a steady compounder in the healthcare devices space.

AVOIDWeak Technical SetupCurrent data points to a weaker relative setup or heavier score deductions.
MEETMEET compares latest EPS results against analyst estimates.

Finlify Score

34.1 / 100

Data Quality

FULL

Penalty

0.0

Sector

Health Care

Close Price

$275.56

+2.06%

52W Range

$269.64 - $392.95

Market Cap

$124.2B

+2.1%

Compared to previous day

2026 Q1 Revenue

$6.0B

-16.1%

Changes from last reporting quarter

2026 Q1 EPS

$1.00

Diluted shares

Analyst Rating

27 Buy7 Hold0 Sell

34 analysts in latest ratings feed

RSI

19.3

<40 oversold

2Y Range Position

6%

-32.2% from high / +3.2% from low

Beta

0.82

Relative to market benchmark

MACD

-6.18

MACD line -14.27 / signal line -8.08

Fundamental Trend

Growth 14.2
Revenue QoQ-16.1%
Revenue YoY+2.6%
EPS QoQ-50.0%
EPS YoY0.0%
Gross margin QoQ-1.2%
Operating margin QoQ-9.6%
Net margin QoQ+0.5%

Financial Health

Quality 61.1
Debt / equity0.62x
Debt ratio+30.7%
Cash / debt proxy0.20x
Cash / assets+6.2%

Data Quality

FULL
As of date2026-09-11
Latest statement2026-03-31
Penalty0.0
Missing dataNone

Valuation Reference

P/E31.64x
P/B6.00x
P/S4.09x
EV / EBITDA26.68x

Price Chart

Close price, two-year source window

Finlify Score

AVOID

34.1 / 100

Relative Strength5.0 / 100
Accumulation & Volume89.5 / 100
Fundamental Trend14.2 / 100
Financial Quality61.1 / 100
Data Quality FULLNo penalty

Score History

Finlify Score and component trend

Financial Statements

Calendar year view. Figures are estimates only. For official figures, refer to the company website.

2026 Q12025 Q42025 Q32025 Q2
Revenue$6.0B-16.1%$7.2B+18.4%$6.1B+0.6%$6.0B+2.7%
Gross Profit$3.8B-17.7%$4.6B+20.1%$3.9B+0.3%$3.8B+2.6%
Operating Income$936M-48.1%$1.8B+58.9%$1.1B+2.0%$1.1B+33.0%
Net Income$745M-12.2%$849M-1.2%$859M-2.8%$884M+35.2%

Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.

AI Signal

Generated Aug 1, 2026

Finlify's signal for SYK is AVOID, with a Finlify Score of 31.4 out of 100, suggesting a generally unfavorable quantitative outlook for the asset at this time.

Technical

The asset's Relative Strength score of 19.3/100 indicates potential underperformance relative to other assets. While SYK has seen positive recent returns, with an 11.1% gain over 20 days and 19.7% over 60 days, it remains 10.2% below its 52-week high. The Accumulation / Volume score of 44.8/100 suggests moderate buying interest.

Fundamentals

The Fundamental Trend score of 14.2/100 appears quite low, indicating a potentially weak or deteriorating fundamental outlook. Valuation multiples, such as a P/E ratio of 38.4x, P/B of 6.0x, and P/S of 5.0x, may suggest the asset is trading at a premium. Despite this, the Financial Quality score of 61.1/100 indicates reasonable underlying financial health, and the asset offers a dividend yield of 1.01%.

Macro Context

The prevailing macro environment, characterized by elevated inflation (CPI YoY at 3.7%, Core PCE at 3.3%) and higher interest rates (10Y Treasury Yield at 4.7%), may present headwinds for growth-oriented assets like SYK, potentially impacting its valuation and future performance.

Key Risks

  • The very low Fundamental Trend score of 14.2/100 suggests a concerning deterioration in underlying business performance or outlook.
  • Elevated valuation multiples, including a P/E of 38.4x and P/B of 6.0x, may indicate limited upside or increased risk if growth expectations are not met.
  • The recent earnings 'MISS' and the next earnings date being today (2026-07-30) could introduce significant volatility and further pressure on the stock.